[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophenia-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophenia-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,73,110,140,164,191,219,231,260,284],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054230","phase-4-exercise-and-olanzapine-samidorphan-100054230",false,"NCT06740890","Exercise and Olanzapine-samidorphan","A Proof of Concept Study of Time Limited Exercise Plus Olanzapine-samidorphan for the Prevention of Early Weight Gain","Inclusion Criteria:\n\n1. Age between 18-65, inclusive at Visit 1.\n2. DSM-V diagnosis of schizophrenia or schizoaffective or Bipolar I\u002FII\u002FNOS disorder at Visit 1.\n3. Body Mass Index (BMI) of 18.0-40.0 kg\u002Fm2, inclusive, at Visits 1 and 2.\n4. Willing to provide informed consent at Visit 1.\n5. Medically and psychiatrically stable for study participation at Visit 1.\n6. Responsive to an antipsychotic treatment (other than clozapine) in the past 5 years prior to Visit 1.\n7. Can benefit from participation in this study and has a reason to participate, such as inadequate efficacy on current treatment, side effects on current treatment, desire to start olanzapine-samidorphan or try structured exercise program (assessed at Visit 1).\n8. Maintained a stable body weight (change \\\u003C 5%) for at least 3 months prior to Visit 1.\n9. Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for women of childbearing potential only) (assessed at Visit 1 and Visit 2).\n\nExclusion Criteria:\n\n1. Positive drug screen for opioids, phencyclidine, amphetamine\u002F methamphetamine, or cocaine at Visit 1 or Visit 2.\n2. Diagnosis of moderate or severe substance use disorder, anorexia nervosa, bulimia, binge eating disorder or any other clinically significant eating disorder at Visit 1.\n3. EKG abnormality that is clinically significant including a QT interval \\> 450 msec for men and \\> 470 msec for women, as corrected by the Fridericia formula (QTcF) at Visit 1.\n4. Use of olanzapine+samidorphan for any reason in the last six months prior to Visit 1, any history of poor or inadequate response to treatment with olanzapine or no justifiable reason to expect improvement on olanzapine as assessed at Visit 1.\n5. Taken opioid agonists (e.g., codeine, oxycodone, tramadol, or morphine) within the 14 days prior to Visit 1 and\u002For anticipates a need to take opioid medication during the study period (e.g., planned surgery), or has taken opioid antagonists including naltrexone (any formulations) or naloxone within 60 days prior to Visit 1.\n6. Pregnant or breast feeding women. Women of child-bearing potential must have a negative serum beta-hCG pregnancy test at Visit 1 and a negative urine pregnancy test at Visit 2.\n7. Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise subject safety on study medication or exercise, or adversely affect the evaluation of efficacy, including (but not necessarily limited to) the following (as assessed at Visit 1):\n\n   1. Clinically significant hypotension or hypertension not stabilized on medical therapy.\n   2. Unstable thyroid dysfunction in the past 6 months (e.g., hypothyroidism, hyperthyroidism, or thyroiditis that was untreated, or discovered and treatment was initiated within the 6 months prior to screening).\n   3. Personal or family history of neuroleptic malignant syndrome, has a history of clinically significant extrapyramidal symptoms when taking olanzapine, or has had clinically significant tardive dyskinesia.\n   4. Neurological conditions include the following:\n\n      * History of seizure disorder or a condition associated with seizures (except history of febrile seizures).\n      * History of brain tumor, subdural hematoma, stroke or any other clinically significant neurological condition within the 12 months prior to Visit 1.\n      * Head trauma with loss of consciousness within the 12 months prior to Visit 1.\n      * Active, acute or chronic CNS infection.\n   5. Cardiac condition that might confound study results, pose additional risk when administering the study drug or exercise regimen to the subject, or preclude successful completion of the study. Conditions include the following:\n\n      * Clinically significant cardiac arrhythmia, cardiomyopathy, a cardiac conduction defect, or a history of myocardial infarction or unstable angina within 6 months prior to Visit 1.\n8. Currently taking any contraindicated medications as per the approved labeling for Olz-Sam (see section 6.5 for details) at Visit 1 and Visit 2.\n9. Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 3 months prior to Visit 1 or current at Visit 2\n10. Inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss at Visit 1.\n11. Joined a weight management program or had significant changes in diet or exercise regimen within 6 weeks prior to Visit 1 or plans to join a weight management program during the study as assessed at Visit 1.\n12. History of diabetes (assessed at Visit 1).\n13. Laboratory abnormality that would compromise the well-being of the subject, or any of the following specific laboratory results at Visit 1:\n\n    1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \\> 2 times the upper limit of the laboratory normal reference range\n    2. Absolute neutrophil count (ANC) \\\u003C1.5 x 10\\^3 μL\n    3. Platelet count \\\u003C 75 x 10\\^3 uL\n    4. Serum creatinine \\> 1.5 mg\u002FdL\n    5. Dyslipidemia, defined for this study as total fasting cholesterol \\> 280 mg\u002FdL or fasting triglycerides \\> 500 mg\u002FdL\n    6. Hemoglobin A1c (HbA1c) \\> 6.0%\n    7. Fasting plasma glucose \\> 126 mg\u002FdL (7.0 mmol\u002FL)\n14. Is not fit for the trial in the opinion of the investigator at Visit 1 and Visit 2.","ALL","18 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I\u002FII\u002FNOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz\u002FSam) plus four weeks of aerobic exercise.",[27,28,29,30],"Schizophenia Disorder","Schizoaffective Disorder","Bipolar Disorder I or II","Bipolar Disorder NOS",[32,33,34],"Exercise","Antipsychotic induced weight gain","olanzapine-samidorphan","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2025-06-26",{"date":43,"type":21},"2027-04",{"name":45,"class":46},"New York State Psychiatric Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100590618","phase-4-biomarkers-to-enhance-early-schizophrenia-treatment-100590618","NCT06969755","Biomarkers to Enhance Early Schizophrenia Treatment","BEEST","Inclusion Criteria:\n\n1. Aged 18 to 35.\n2. DSM5 diagnosis (as determined by the SCID5) of schizophrenia, schizoaffective disorder, schizophreniform disorder.\n3. Current positive symptoms rated ≥4 (moderate) on one or more of the following BPRS positive subscale items: unusual thought content, conceptual disorganization, hallucinatory behavior, suspiciousness.\n4. Preserved striatal connectivity, as determined by screening MRI scan\n5. Absence of the MC4R high-risk genotype, as determined by genetic testing\n6. Absence of the HLA-DQB1 high-risk genotype, as determined by genetic testing\n7. In an early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 4 weeks or less (with exceptions of very low doses for other off-label indications, e.g. sleep)\n8. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. The patient reports or medical records state a serious neurological or endocrine disorder at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements\n2. An abnormal EKG at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements\n3. Any medical condition which requires treatment with a medication with psychotropic effects.\n4. Significant risk of suicidal or homicidal behavior (i.e. 'severe' risk on the Columbia Suicide Scale, a 'hostility' score of 7 on the BPRS, or an answer of 'yes' on questions 4,5 or 6 on the CDSS).\n5. Cognitive limitations, or any other factor that would preclude potential participants providing informed consent\n6. Contraindications to MRI (e.g. pacemaker).\n7. Meeting SCID-5 substance use disorder moderate or severe for any substance, other than nicotine within 3 months of screening visit. Meeting SCID5 substance use disorder mild for any substance other than cannabis, alcohol, or nicotine for less than 3 months prior to screening visit, or a positive urine baseline drug screen with a substance other than nicotine, alcohol, or cannabis\n8. Suspected DSM5 intellectual disability based upon clinical interview and psychosocial history, as well as screening with the Weschler Test for Adult Reading (IQ score \\\u003C71)\n9. Prior psychosurgery\n10. Pregnancy (self-report)\n11. Seizure disorder (self-report)\n\n    \\-","35 Years",{"count":57,"type":21},180,[24],"This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.",[27],[62],"Schizophrenia","2026-06-11",{"date":65,"type":39},"2026-06-12",{"date":67,"type":39},"2025-09-30",{"date":69,"type":21},"2030-07-30",{"name":71,"class":46},"Northwell Health",5,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":47},"100581888","a-novel-blood-test-as-a-biomarker-in-mental-health-100581888","NCT06856161","A Novel Blood Test as a Biomarker in Mental Health","A Novel Blood Test as a Differential Diagnosis and Drug Efficacy Biomarker in Mental Health","LEADING-MH","Inclusion Criteria:\n\nI. Age 19+. II. Informed consent by participant\n\nIII. Any of the following situations:\n\n1. Suspected, new onset or established depression.\n2. First episode of psychosis or suspected\u002Festablished schizophrenia. IV. In the opinion of the Investigator, the participant will likely be able to complete the standardized mental health questionnaires administered in each study visit.\n\nExclusion Criteria:\n\nI. Inability to provide informed consent. II. Currently enrolled in any other research study involving drugs or devices that may confound mental health treatment outcomes.\n\nIII. Currently declared on extended leave Under British Columbia's Mental Health Act.","19 Years",{"count":83,"type":21},500,"OBSERVATIONAL","This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis\u002FSchizophrenia (PSY).",[87,27,88,89,90,91,92,93],"Depression - Major Depressive Disorder","Psychosis","Mania (Neurotic)","Alcohol Consumption","Anxiety Disorder (Panic Disorder or GAD)","Substance Use Disorders","Alcohol Use Disorder",[95,96,97,98,99,100],"mental health","biomarker","depression","schizophrenia","psychosis","SERT","2026-03-03",{"date":103,"type":39},"2026-03-05",{"date":105,"type":39},"2025-03-25",{"date":107,"type":21},"2027-08-31",{"name":109,"class":46},"Fraser Health",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":72},"100626922","effects-of-smoking-on-network-connectivity-in-patients-with-schizophrenia-symptoms-in-scz-patients-100626922","NCT07441928","Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients","Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Acceptance and Commitment Therapy for Smoking Cessation and Reduction of Psychotic Symptoms in Patients With Schizophrenia","ACT","Inclusion Criteria:\n\n* Individuals who have been diagnosed with schizophrenia or schizoaffective disorder and after at least one-year followup;\n* currently taking anti-psychotic medications for ≥ 3 months with good compliance;\n* aged 18 years or above;\n* able to communicate in Cantonese\n\nExclusion Criteria:\n\n* Have any other current or past psychotic disorders;\n* with fleeting or actual suicidal\u002Fself-harm ideations, or acting-out behavior in the past;\n* with a known history of violence\u002Faggression and a forensic history\n* Categorized with special care or intensive care (e.g., arson, battery, physical assault, rape, murder, etc.)\n* Have a lifetime history of substance abuse and\u002For are currently receiving treatment for substance abuse (e.g., opioids, cocaine, marijuana, or stimulants);\n* With alcohol consumption exceeding 25 standard drinks\u002Fweek for men and 20 standard drinks\u002Fweek for women over the last 6 months;\n* Have received a diagnosis of alcohol or drug dependence in the year preceding recruitment;\n* Are pregnant, breast-feeding, or planning a pregnancy for the duration of the study;\n* Have a history or current diagnosis of attention-deficit hyperactivity disorder (ADHD);\n* Have a history of epilepsy or a seizure disorder;\n* Experience disorientation, have developmental disabilities, and\u002For an organic mental disorder;\n* fMRI-related exclusion criteria promulgated by University Research Facility in Behavioural and Systems Neuroscience (UBSN), PolyU",{"count":119,"type":21},90,[121],"NA","The prevalence of smoking among people with schizophrenia (SCZ) is substantially higher at 54% to 90% (McClave et al., 2010). About half of all deaths amongst people with scz are attributed to smoking-related diseases and cancer involving the lung, the cardiovascular system, and the liver (Kely et al., 2011; WHO, 2019). Acceptance and commitment therapy (ACT) is effective for treating psychotic symptoms and addictive behaviours. In a local randomised controlled trial comparing individual ACT to social support for smoking cessation in adult scz smokers, the self-reported quit rates in ACT group were higher than in the social support group (6 months: 12.3% vs. 7.7%, p=0.56 ; 12 months: 10.8% vs. 7.7%, p=0.76; Mak, Loke, and Leung, 2021). In this study, functional neuroimaging (fMRI) will be combined with symptoms assessment in order to ascertain whether group-based ACT is effective in modifying the brain's responses in general and specifically to tobacco craving cues and resting-state functional connectivity in three time points (pre-, post-intervention, and 6-month follow-up) among people with schizophrenia.",[124,27],"Smoking Cessation",[126,127,128,129,130],"Schizophrenia (SCZ)","smoking cessation","Functional neuroimaging (fMRI)","Acceptance and Commitment therapy (ACT)","psychotic symptoms","2026-02-26",{"date":133,"type":39},"2026-03-02",{"date":135,"type":39},"2023-03-01",{"date":137,"type":21},"2026-04-30",{"name":139,"class":46},"The Hong Kong Polytechnic University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100582640","context-aware-mobile-intervention-for-social-recovery-in-serious-mental-illness-r33-100582640","NCT06865937","Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)","Inclusion Criteria:\n\n* Voluntary informed consent to participate and capacity to consent; Age 18 to 65;\n* Diagnosis of schizophrenia, schizoaffective, bipolar I disorder or major depression with history of psychosis based on a diagnostic interview and available medical record review;\n* Minimum level of social avoidance defined by a score of ≥ 2 on the Scale for the Assessment of Negative Symptoms (SANS) asociality item;\n* Be willing and able to speak English at ≥ 6th grade reading level (to read intervention workbook).\n\nExclusion Criteria:\n\n* Prior cognitive-behavioral therapy in the past 2 years;\n* Greater than moderate disorganization on the PANSS (P2- Disorganization item \\>5);\n* Alcohol or substance dependence in past 3 months based on the diagnostic interview;\n* Level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness);\n* Unable to adequately see or manually manipulate a phone;\n* Resident of an integrated housing facility that also provides treatment services.",{"count":147,"type":21},125,[121],"This randomized clinical trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.",[27,28],[98,152,153,154],"serious mental illness","social engagement","randomized clinical trial","2026-02-20",{"date":157,"type":39},"2026-02-23",{"date":159,"type":39},"2025-07-01",{"date":161,"type":21},"2028-09-30",{"name":163,"class":46},"University of California, San Diego",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":172,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":47},"100616504","effects-of-schizophrenia-and-bipolar-disorder-on-exercise-capacity-pulmonary-function-and-quality-of-life-100616504","NCT07306468","Effects of Schizophrenia and Bipolar Disorder on Exercise Capacity, Pulmonary Function, and Quality of Life","Investigation of Exercise Capacity, Pulmonary Function, Respiratory Muscle Strength, and Quality of Life in Patients Diagnosed With Schizophrenia and Bipolar Disorder","Inclusion Criteria:\n\n* Being volunteer for participation\n* Being 18 to 65 age\n\nExclusion Criteria:\n\n* Having any respiratory, cardiac, neurologic or orthopedic disease which may affect respiratory functions or exercise capacity\n* Having any neuropsychiatric disease except schizophrenia or bipolar disorder",true,{"count":173,"type":21},150,"This observational study aims to evaluate exercise capacity, pulmonary function, respiratory muscle strength, and quality of life in individuals diagnosed with schizophrenia and bipolar disorder. These psychiatric conditions are associated with sedentary lifestyles, metabolic side effects of psychotropic medications, and increased comorbidity risks, all of which may negatively impact physical fitness and respiratory health. By assessing cardiorespiratory endurance, pulmonary parameters (FVC, FEV₁), and respiratory muscle strength in this population, the study seeks to identify physiological limitations and contribute to the development of more effective rehabilitation strategies. The findings may support multidisciplinary approaches to improving physical health and overall quality of life in individuals with severe mental illness.",[27,176],"Bipolar Disorder (BD)",[98,178,179,180,181],"bipolar disorder","respiratory functions","quality of life","exercise capacity","2025-12-14",{"date":184,"type":39},"2025-12-29",{"date":186,"type":39},"2025-11-01",{"date":188,"type":21},"2026-12-01",{"name":190,"class":46},"Çankırı Karatekin University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":47},"100579987","effectiveness-of-digital-cognitive-behavioral-therapy-for-the-treatment-of-depression-a-real-world-study-100579987","NCT06831435","Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study","Inclusion Criteria:\n\n1. Aged 14-60 years (including 14 and 60), no gender restriction;\n2. HAMD \\>= 14;\n3. Written informed consent obtained from the patient; written informed consent obtained from the guardian for minors.\n\nExclusion Criteria:\n\n* Persons with severe suicidal tendencies (item 10 of the MADRS scale ≥ 5).","14 Years","60 Years",{"count":200,"type":21},325,[121],"The project proposes to develop a digital product based on cognitive behavioral therapy for the assisted treatment of depression. The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including AI-guided course work and homework. This study aims to evaluate the therapeutic effects of CBT-based digital products for depression in patients through a real-world study, and to explore its genetic and neuroimaging mechanisms.",[204,205,27,206],"Depression","Bipolar Affective Disorder","Psychiatric &Amp;or Mood Disorder",[208,209],"i-CBT","a real-world study","2025-12-08",{"date":212,"type":39},"2025-12-15",{"date":214,"type":39},"2024-11-13",{"date":216,"type":21},"2026-12-31",{"name":218,"class":46},"Peking University",{"id":220,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":25,"conditions":223,"keywords":224,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":230,"locationsCount":47},"100573024",{"count":20,"type":21},[24],[27,28,29,30],[32,33,34],"2025-07-08",{"date":227,"type":39},"2025-07-11",{"date":41,"type":39},{"date":43,"type":21},{"name":45,"class":46},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":171,"sex":16,"minAge":237,"maxAge":18,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":249,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100588253","the-effectiveness-of-combining-arvr-technology-in-virtual-clinical-auditory-hallucinations-on-the-comprehensive-auditory-hallucination-nursing-competency-of-psychiatric-nurses-100588253","NCT06938997","The Effectiveness of Combining AR\u002FVR Technology in Virtual Clinical Auditory Hallucinations on the Comprehensive Auditory Hallucination Nursing Competency of Psychiatric Nurses","Inclusion Criteria:\n\n* A psychiatric nurse who has been engaged in nursing work in a psychiatric unit for at least three months;\n* Those who were willing to participate in the study and filled out the consent form;\n* Willing to use smartphones to watch VR360 videos;\n* Willing to cooperate with the study and use 3D glasses.\n\nExclusion Criteria:\n\n* Nurses who are about to leave or be transferred out of the psychiatric ward within six months\n* Part-time nurses\n* Part-time supervisors\n* Specialist nurses.","20 Years",{"count":239,"type":21},200,[121],"This study aims to develop and evaluate a Virtual Reality (VR) Auditory Hallucination Program to enhance psychiatric nurses' comprehensive care competence in managing auditory hallucinations among patients with schizophrenia. Given that 60-80% of patients on the schizophrenia spectrum experience auditory hallucinations, and many continue to do so despite medication, improving nurses' professional skills in this area is critical.\n\nThe research is conducted in two phases across four psychiatric institutions. Phase one involves the development and validation of the VR program and an OSCE (Objective Structured Clinical Examination), piloted with five participants and evaluated by psychiatric nursing experts. Phase two is a formal interventional study with 200 psychiatric nurses, using block randomization and three data collection time points.\n\nAssessment tools include five instruments measuring nurses' confidence, knowledge, attitude, empathy, immersion, and care performance related to auditory hallucinations. The study expects to strengthen nurses' ability to assess and manage auditory hallucinations effectively, and proposes the VR program as a potential tool for nursing in-service education.",[243,27,244],"Nurses","Hallucinations, Auditory",[246,247,98,248],"Auditory hallucination care competence","virtual reality","Objective Structured Clinical Examination","NOT_YET_RECRUITING","2025-05-05",{"date":252,"type":39},"2025-05-08",{"date":254,"type":21},"2025-05-01",{"date":256,"type":21},"2027-05-01",{"name":258,"class":46},"National Yang Ming Chiao Tung University",4,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":171,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":267,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":249,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100582922","cracking-the-heterogeneity-of-social-outcome-through-neuropsychophysiological-profiles-100582922","NCT06869616","CRacking the HEterogeneity of Social Outcome Through Neuropsychophysiological Profiles","CRHESO","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of Schizophrenia according to DSM V criteria\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Intellectual disability\n* Neurological disorder",{"count":268,"type":21},100,"CRHESO aims at overcoming the considerable burden of mental disorders, which affects both psychosocial well-being and societal welfare, through a multidisciplinary and integrated approach to explore and remediate dimensions affecting social outcome.",[27],[272,273,274,275],"electrophysiology","metaphor comprehension","language disorder","social functioning","2025-03-05",{"date":278,"type":39},"2025-03-11",{"date":254,"type":21},{"date":281,"type":21},"2028-01-01",{"name":283,"class":46},"IRCCS San Raffaele",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":291,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":249,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":47},"100569955","evaluating-pharmacogenomics-based-pharmacotherapy-in-real-world-settings-for-schizophrenia-100569955","NCT06700967","Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia","A Precision Medication Guidance Model for Schizophrenia Based on Pharmacogenomics and Physiologically Based Pharmacokinetics: a Real-World Observational Study","Inclusion Criteria:\n\n1. Suffer from schizophrenia (as assessed in agreement with ICD-11 criteria).\n2. Age between ≥18 and \\\u003C65 years.\n3. Currently receiving inpatient or outpatient psychiatric treatment.\n4. Experienced any of the following suboptimal treatment conditions while receiving antipsychotic medication within the therapeutic dosage range:\n\n   1. Standard antipsychotic treatment for more than 2 weeks with the occurrence of drug-induced adverse effects requiring dose adjustment or a switch of medication.\n   2. Antipsychotic treatment within the therapeutic dosage range for more than 4 weeks, with the presence of at least two items of the Positive and Negative Syndrome Scale (PANSS) (P1, P2, P3, N1, N4, N6, G5, and G9) score ≥4, or a total PANSS score \\>70, or a CGI-S score ≥4.\n   3. Other situations where a change in medication is deemed necessary, as assessed by senior clinical physicians.\n5. Understand the study requirements and provide written informed consent to participate; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.\n\nExclusion Criteria:\n\n1. Presence of organic brain disease or a severe and\u002For unstable physical condition.\n2. Substance abuse or dependence within the past 6 months or currently.\n3. Presence of elevated levels of agitation, impulsivity, or risk of self-injury or suicide.\n4. Pregnant or breastfeeding women.\n5. The presence of any other conditions that may render the individual ineligible for participation in this clinical trial.",{"count":292,"type":21},400,"An 8-week, rater-blinded, real-world observational study to investigate the benefits of pharmacogenetics-based pharmacotherapy in patients suffering from schizophrenia.",[27],"2024-11-20",{"date":297,"type":39},"2024-11-22",{"date":299,"type":21},"2024-12-01",{"date":301,"type":21},"2025-12-31",{"name":303,"class":46},"Shanghai Mental Health Center"]